{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T03:59:15Z","timestamp":1791172755963,"version":"4.1.0"},"reference-count":145,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","cell.com","clinicalkey.es","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.tips.2013.11.006","type":"journal-article","created":{"date-parts":[[2014,1,14]],"date-time":"2014-01-14T08:46:15Z","timestamp":1389689175000},"page":"86-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":231,"title":["Current progress in antiviral strategies"],"prefix":"10.1016","volume":"35","author":[{"given":"Zhiyong","family":"Lou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuna","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihe","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2013.11.006_bib0005","doi-asserted-by":"crossref","first-page":"12438","DOI":"10.1073\/pnas.1307382110","article-title":"Molecular architecture of the uncleaved HIV-1 envelope glycoprotein trimer","volume":"110","author":"Mao","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tips.2013.11.006_bib0010","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/COH.0b013e328363a90e","article-title":"Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site","volume":"8","author":"Georgiev","year":"2013","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.tips.2013.11.006_bib0015","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/BF01309464","article-title":"Biological and pharmacokinetic properties of a novel immunoglobulin\u2013CD4 fusion protein","volume":"139","author":"Lyczak","year":"1994","journal-title":"Arch. Virol."},{"key":"10.1016\/j.tips.2013.11.006_bib0020","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-112-4-247","article-title":"Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A Phase I\u2013II escalating dosage trial","volume":"112","author":"Schooley","year":"1990","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.tips.2013.11.006_bib0025","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1128\/AAC.48.2.423-429.2004","article-title":"Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542","volume":"48","author":"Jacobson","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tips.2013.11.006_bib0030","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1128\/AAC.00759-10","article-title":"Antiviral activity, pharmacokinetics, and safety of BMS-488043, a novel oral small-molecule HIV-1 attachment inhibitor, in HIV-1-infected subjects","volume":"55","author":"Hanna","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tips.2013.11.006_bib0035","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1128\/AAC.00426-12","article-title":"In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068","volume":"56","author":"Nowicka-Sans","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tips.2013.11.006_bib0040","doi-asserted-by":"crossref","first-page":"12531","DOI":"10.1128\/JVI.01889-13","article-title":"A mutant influenza virus that uses an n1 neuraminidase as the receptor-binding protein","volume":"87","author":"Hooper","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2013.11.006_bib0045","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/303041a0","article-title":"Structure of the catalytic and antigenic sites in influenza virus neuraminidase","volume":"303","author":"Colman","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.tips.2013.11.006_bib0050","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/303035a0","article-title":"Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9A resolution","volume":"303","author":"Varghese","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.tips.2013.11.006_bib0055","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.coviro.2011.09.002","article-title":"Antivirals and resistance: influenza virus","volume":"1","author":"Ison","year":"2011","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.tips.2013.11.006_bib0060","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3851\/IMP1688","article-title":"Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza","volume":"21","author":"Yamashita","year":"2010","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.tips.2013.11.006_bib0065","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/cid\/cir001","article-title":"Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States","volume":"52","author":"Hernandez","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tips.2013.11.006_bib0070","doi-asserted-by":"crossref","first-page":"5755","DOI":"10.1128\/JVI.02733-12","article-title":"Crystal structure of enterovirus 71 RNA-dependent RNA polymerase complexed with its protein primer VPg: implication for a trans mechanism of VPg uridylylation","volume":"87","author":"Chen","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2013.11.006_bib0075","doi-asserted-by":"crossref","first-page":"13662","DOI":"10.1128\/JVI.01712-12","article-title":"Enterovirus 71 VPg uridylation uses a two-molecular mechanism of 3D polymerase","volume":"86","author":"Sun","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2013.11.006_bib0080","doi-asserted-by":"crossref","first-page":"e1003255","DOI":"10.1371\/journal.ppat.1003255","article-title":"Rational engineering of recombinant picornavirus capsids to produce safe, protective vaccine antigen","volume":"9","author":"Porta","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.tips.2013.11.006_bib0085","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1099\/vir.0.020420-0","article-title":"Crystal structure of equine rhinitis A virus in complex with its sialic acid receptor","volume":"91","author":"Fry","year":"2010","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.tips.2013.11.006_bib0090","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/344070a0","article-title":"A soluble form of intercellular adhesion molecule-1 inhibits rhinovirus infection","volume":"344","author":"Marlin","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.tips.2013.11.006_bib0095","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0166-3542(99)00061-3","article-title":"Inhibitory effect of dibenzofuran and dibenzosuberol derivatives on rhinovirus replication in vitro; effective prevention of viral entry by dibenzosuberenone","volume":"44","author":"Murray","year":"1999","journal-title":"Antiviral Res."},{"key":"10.1016\/j.tips.2013.11.006_bib0100","doi-asserted-by":"crossref","first-page":"9770","DOI":"10.1073\/pnas.91.21.9770","article-title":"Peptides corresponding to a predictive \u03b1-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection","volume":"91","author":"Wild","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tips.2013.11.006_bib0105","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/3293","article-title":"Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry","volume":"4","author":"Kilby","year":"1998","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2013.11.006_bib0110","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1089\/088922202760072294","article-title":"The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults","volume":"18","author":"Kilby","year":"2002","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.tips.2013.11.006_bib0115","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/00002030-200303280-00007","article-title":"A Phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy","volume":"17","author":"Lalezari","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.tips.2013.11.006_bib0120","doi-asserted-by":"crossref","first-page":"16332","DOI":"10.1073\/pnas.0807335105","article-title":"Potent HIV fusion inhibitors against enfuvirtide-resistant HIV-1 strains","volume":"105","author":"He","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tips.2013.11.006_bib0125","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.2174\/1381612811319100004","article-title":"Synthesized peptide inhibitors of HIV-1 gp41-dependent membrane fusion","volume":"19","author":"He","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.tips.2013.11.006_bib0130","doi-asserted-by":"crossref","first-page":"12772","DOI":"10.1073\/pnas.0701478104","article-title":"Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus","volume":"104","author":"Dwyer","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tips.2013.11.006_bib0135","doi-asserted-by":"crossref","first-page":"11126","DOI":"10.1074\/jbc.M800200200","article-title":"Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor","volume":"283","author":"He","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2013.11.006_bib0140","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S1359-6446(05)03575-0","article-title":"PEGylation, successful approach to drug delivery","volume":"10","author":"Veronese","year":"2005","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.tips.2013.11.006_bib0145","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/jps.20319","article-title":"Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins","volume":"94","author":"Sinclair","year":"2005","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.tips.2013.11.006_bib0150","doi-asserted-by":"crossref","first-page":"4987","DOI":"10.1128\/AAC.00670-09","article-title":"ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formation","volume":"53","author":"Wang","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tips.2013.11.006_bib0155","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1021\/jm101014v","article-title":"Design, synthesis, and biological activity of novel 5-((arylfuran\/1H-pyrrol-2-yl)methylene)-2-thioxo-3-(3-(trifluoromethyl)phenyl)thi azolidin-4-ones as HIV-1 fusion inhibitors targeting gp41","volume":"54","author":"Jiang","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2013.11.006_bib0160","doi-asserted-by":"crossref","first-page":"7631","DOI":"10.1021\/jm900450n","article-title":"Design, synthesis, and structure\u2013activity relationship of a novel series of 2-aryl 5-(4-oxo-3-phenethyl-2-thioxothiazolidinylidenemethyl)furans as HIV-1 entry inhibitors","volume":"52","author":"Katritzky","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2013.11.006_bib0165","doi-asserted-by":"crossref","first-page":"7288","DOI":"10.1128\/JVI.00535-10","article-title":"A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41","volume":"84","author":"Murray","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2013.11.006_bib0170","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/nsmb.1456","article-title":"Viral membrane fusion","volume":"15","author":"Harrison","year":"2008","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.tips.2013.11.006_bib0175","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1038\/ncomms2889","article-title":"Picornavirus uncoating intermediate captured in atomic detail","volume":"4","author":"Ren","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2013.11.006_bib0180","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00705-011-1222-6","article-title":"In vitro and in vivo evaluation of ribavirin and pleconaril antiviral activity against enterovirus 71 infection","volume":"157","author":"Zhang","year":"2011","journal-title":"Arch. Virol."},{"key":"10.1016\/j.tips.2013.11.006_bib0185","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0166-3542(01)00206-6","article-title":"Treatment of picornavirus infections","volume":"53","author":"Rotbart","year":"2002","journal-title":"Antiviral Res."},{"key":"10.1016\/j.tips.2013.11.006_bib0190","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1006\/jmbi.1995.0637","article-title":"A novel basis of capsid stabilization by antiviral compounds","volume":"254","author":"Phelps","year":"1995","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.tips.2013.11.006_bib0195","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1006\/jmbi.1999.3483","article-title":"Stabilization of poliovirus by capsid-binding antiviral drugs is due to entropic effects","volume":"296","author":"Tsang","year":"2000","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.tips.2013.11.006_bib0200","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1021\/jm010536a","article-title":"Design, synthesis, and structure\u2013activity relationship of pyridyl imidazolidinones: a novel class of potent and selective human enterovirus 71 inhibitors","volume":"45","author":"Shia","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2013.11.006_bib0205","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1073\/pnas.59.3.966","article-title":"Evidence for large precursor proteins in poliovirus synthesis","volume":"59","author":"Summers","year":"1968","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tips.2013.11.006_bib0210","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1432-1033.1978.tb12260.x","article-title":"Translation of encephalomyocarditis virus RNA in vitro yields an active proteolytic processing enzyme","volume":"85","author":"Pelham","year":"1978","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.tips.2013.11.006_bib0215","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1099\/vir.0.19424-0","article-title":"Mechanisms and enzymes involved in SARS coronavirus genome expression","volume":"84","author":"Thiel","year":"2003","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.tips.2013.11.006_bib0220","doi-asserted-by":"crossref","first-page":"13600","DOI":"10.1128\/JVI.78.24.13600-13612.2004","article-title":"Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity","volume":"78","author":"Harcourt","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2013.11.006_bib0225","doi-asserted-by":"crossref","first-page":"5717","DOI":"10.1073\/pnas.0510851103","article-title":"Severe acute respiratory syndrome coronavirus papain-like protease: structure of a viral deubiquitinating enzyme","volume":"103","author":"Ratia","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tips.2013.11.006_bib0230","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.molcel.2007.01.033","article-title":"Structure of a herpesvirus-encoded cysteine protease reveals a unique class of deubiquitinating enzymes","volume":"25","author":"Schlieker","year":"2007","journal-title":"Mol. Cell"},{"key":"10.1016\/j.tips.2013.11.006_bib0235","doi-asserted-by":"crossref","first-page":"6323","DOI":"10.1128\/JVI.76.12.6323-6331.2002","article-title":"Deubiquitinating function of adenovirus proteinase","volume":"76","author":"Balakirev","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2013.11.006_bib0240","doi-asserted-by":"crossref","first-page":"7832","DOI":"10.1128\/JVI.00217-10","article-title":"The cysteine protease domain of porcine reproductive and respiratory syndrome virus nonstructural protein 2 possesses deubiquitinating and interferon antagonism function","volume":"84","author":"Sun","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2013.11.006_bib0245","first-page":"112","article-title":"From TMC114 to darunavir: five years of data on efficacy","volume":"15","author":"Llibre","year":"2013","journal-title":"AIDS Rev."},{"key":"10.1016\/j.tips.2013.11.006_bib0250","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00001432-200102000-00005","article-title":"Implications of antiretroviral resistance on viral fitness","volume":"14","author":"Nijhuis","year":"2001","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.tips.2013.11.006_bib0255","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S1473-3099(12)70060-9","article-title":"Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care","volume":"12","author":"Pearlman","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.tips.2013.11.006_bib0260","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s40265-013-0017-3","article-title":"HIV protease inhibitors in pregnancy: pharmacology and clinical use","volume":"73","author":"Andany","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.tips.2013.11.006_bib0265","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.antiviral.2006.05.012","article-title":"Rational design of polymerase inhibitors as antiviral drugs","volume":"71","author":"Oberg","year":"2006","journal-title":"Antiviral Res."},{"key":"10.1016\/j.tips.2013.11.006_bib0270","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2174\/187152609787847758","article-title":"Drug targets in cytomegalovirus infection","volume":"9","author":"Andrei","year":"2009","journal-title":"Infect. Disord. Drug Targets"},{"key":"10.1016\/j.tips.2013.11.006_bib0275","first-page":"617","article-title":"Entecavir (Bristol-Myers Squibb)","volume":"2","author":"Billich","year":"2001","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.tips.2013.11.006_bib0280","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/MJT.0b013e318155a191","article-title":"New drugs for chronic hepatitis B: a review","volume":"15","author":"Palumbo","year":"2008","journal-title":"Am. J. Ther."},{"key":"10.1016\/j.tips.2013.11.006_bib0285","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.coph.2012.06.005","article-title":"Antiviral drug advances in the treatment of human immunodeficiency virus (HIV) and chronic hepatitis C virus (HCV)","volume":"12","author":"Wegzyn","year":"2012","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.tips.2013.11.006_bib0290","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1021\/jm00132a002","article-title":"A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine","volume":"32","author":"Miyasaka","year":"1989","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2013.11.006_bib0295","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1021\/jm00105a055","article-title":"A new class of HIV-1-specific 6-substituted acyclouridine derivatives: synthesis and anti-HIV-1 activity of 5- or 6-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT)","volume":"34","author":"Tanaka","year":"1991","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2013.11.006_bib0300","doi-asserted-by":"crossref","first-page":"6863","DOI":"10.1073\/pnas.88.15.6863","article-title":"Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity","volume":"88","author":"Goldman","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tips.2013.11.006_bib0305","doi-asserted-by":"crossref","first-page":"5364","DOI":"10.2174\/092986712803833326","article-title":"Structure\u2013activity relationship studies on clinically relevant HIV-1 NNRTIs","volume":"19","author":"Rawal","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.tips.2013.11.006_bib0310","first-page":"614","article-title":"Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections","volume":"8","author":"Beaulieu","year":"2007","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.tips.2013.11.006_bib0315","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s40265-013-0015-5","article-title":"Next-generation integrase inhibitors: where to after raltegravir?","volume":"73","author":"Karmon","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.tips.2013.11.006_bib0320","doi-asserted-by":"crossref","first-page":"e52562","DOI":"10.1371\/journal.pone.0052562","article-title":"Clinical use of HIV integrase inhibitors: a systematic review and meta-analysis","volume":"8","author":"Messiaen","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.tips.2013.11.006_bib0325","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/S0140-6736(12)60917-9","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks","volume":"379","author":"Sax","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2013.11.006_bib0330","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.antiviral.2012.09.007","article-title":"Structural biology of dengue virus enzymes: towards rational design of therapeutics","volume":"96","author":"Noble","year":"2013","journal-title":"Antiviral Res."},{"key":"10.1016\/j.tips.2013.11.006_bib0335","doi-asserted-by":"crossref","first-page":"35638","DOI":"10.1074\/jbc.M400460200","article-title":"A structural basis for the inhibition of the NS5 dengue virus mRNA 2\u2032-O-methyltransferase domain by ribavirin 5\u2032-triphosphate","volume":"279","author":"Benarroch","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2013.11.006_bib0340","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.antiviral.2009.03.001","article-title":"Flaviviral methyltransferase\/RNA interaction: structural basis for enzyme inhibition","volume":"83","author":"Milani","year":"2009","journal-title":"Antiviral Res."},{"key":"10.1016\/j.tips.2013.11.006_bib0345","doi-asserted-by":"crossref","first-page":"32586","DOI":"10.1074\/jbc.M110.129197","article-title":"Structural and functional analyses of a conserved hydrophobic pocket of flavivirus methyltransferase","volume":"285","author":"Dong","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2013.11.006_bib0350","doi-asserted-by":"crossref","first-page":"8730","DOI":"10.1128\/JVI.00384-12","article-title":"Identification of a novel antiviral inhibitor of the flavivirus guanylyltransferase enzyme","volume":"86","author":"Stahla-Beek","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2013.11.006_bib0355","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.bcp.2012.08.012","article-title":"Development of chemical inhibitors of the SARS coronavirus: viral helicase as a potential target","volume":"84","author":"Keum","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.tips.2013.11.006_bib0360","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.antiviral.2012.07.012","article-title":"A screen for modulators of large T antigen's ATPase activity uncovers novel inhibitors of Simian Virus 40 and BK virus replication","volume":"96","author":"Seguin","year":"2012","journal-title":"Antiviral Res."},{"key":"10.1016\/j.tips.2013.11.006_bib0365","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1128\/AAC.49.12.4834-4842.2005","article-title":"Biphenylsulfonacetic acid inhibitors of the human papillomavirus type 6 E1 helicase inhibit ATP hydrolysis by an allosteric mechanism involving tyrosine 486","volume":"49","author":"White","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tips.2013.11.006_bib0370","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1177\/1087057113482586","article-title":"Discovering new medicines targeting helicases: challenges and recent progress","volume":"18","author":"Shadrick","year":"2012","journal-title":"J. Biomol. Screen."},{"key":"10.1016\/j.tips.2013.11.006_bib0375","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1021\/jm034206x","article-title":"Discovery of small-molecule inhibitors of the ATPase activity of human papillomavirus E1 helicase","volume":"47","author":"Faucher","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2013.11.006_bib0380","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1021\/jm8011905","article-title":"Structure-based discovery of triphenylmethane derivatives as inhibitors of hepatitis C virus helicase","volume":"52","author":"Chen","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2013.11.006_bib0385","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3851\/IMP1286","article-title":"Characterization of aurintricarboxylic acid as a potent hepatitis C virus replicase inhibitor","volume":"20","author":"Chen","year":"2009","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.tips.2013.11.006_bib0390","series-title":"Hepatitis C: Antiviral Drug Discovery and Development","first-page":"237","article-title":"NS3 helicase inhibitors","author":"Belon","year":"2011"},{"key":"10.1016\/j.tips.2013.11.006_bib0395","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nrd1853","article-title":"Viral and cellular RNA helicases as antiviral targets","volume":"4","author":"Kwong","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tips.2013.11.006_bib0400","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nrmicro2692","article-title":"The dependence of viral RNA replication on co-opted host factors","volume":"10","author":"Nagy","year":"2012","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.tips.2013.11.006_bib0405","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature08960","article-title":"Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect","volume":"465","author":"Gao","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.tips.2013.11.006_bib0410","doi-asserted-by":"crossref","first-page":"5263","DOI":"10.1016\/S0021-9258(17)30361-7","article-title":"Protein is linked to the 5\u2032 end of poliovirus RNA by a phosphodiester linkage to tyrosine","volume":"253","author":"Ambros","year":"1978","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2013.11.006_bib0415","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/sj.emboj.7600971","article-title":"The structure of a protein primer\u2013polymerase complex in the initiation of genome replication","volume":"25","author":"Ferrer-Orta","year":"2006","journal-title":"EMBO J."},{"key":"10.1016\/j.tips.2013.11.006_bib0420","doi-asserted-by":"crossref","first-page":"9577","DOI":"10.1128\/JVI.00631-08","article-title":"The crystal structure of coxsackievirus B3 RNA-dependent RNA polymerase in complex with its protein primer VPg confirms the existence of a second VPg binding site on Picornaviridae polymerases","volume":"82","author":"Gruez","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2013.11.006_bib0425","doi-asserted-by":"crossref","first-page":"941","DOI":"10.4161\/rna.20345","article-title":"Architecture and regulation of negative-strand viral enzymatic machinery","volume":"9","author":"Kranzusch","year":"2012","journal-title":"RNA Biol."},{"key":"10.1016\/j.tips.2013.11.006_bib0430","doi-asserted-by":"crossref","first-page":"5912","DOI":"10.1093\/nar\/gkt268","article-title":"Nucleocapsid protein structures from orthobunyaviruses reveal insight into ribonucleoprotein architecture and RNA polymerization","volume":"41","author":"Ariza","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.tips.2013.11.006_bib0435","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1126\/science.1228172","article-title":"The structure of native influenza virion ribonucleoproteins","volume":"338","author":"Arranz","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.tips.2013.11.006_bib0440","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1073\/pnas.1200808109","article-title":"Crimean-Congo hemorrhagic fever virus nucleoprotein reveals endonuclease activity in bunyaviruses","volume":"109","author":"Guo","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tips.2013.11.006_bib0445","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1073\/pnas.1016404108","article-title":"Structure of the Lassa virus nucleoprotein reveals a dsRNA-specific 3\u2032 to 5\u2032 exonuclease activity essential for immune suppression","volume":"108","author":"Hastie","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tips.2013.11.006_bib0450","doi-asserted-by":"crossref","first-page":"19365","DOI":"10.1073\/pnas.1108515108","article-title":"Crystal structure of the Lassa virus nucleoprotein\u2013RNA complex reveals a gating mechanism for RNA binding","volume":"108","author":"Hastie","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tips.2013.11.006_bib0455","doi-asserted-by":"crossref","first-page":"9048","DOI":"10.1073\/pnas.1222552110","article-title":"Bunyamwera virus possesses a distinct nucleocapsid protein to facilitate genome encapsidation","volume":"110","author":"Li","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tips.2013.11.006_bib0460","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1126\/science.1227270","article-title":"Organization of the influenza virus replication machinery","volume":"338","author":"Moeller","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.tips.2013.11.006_bib0465","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/nature09605","article-title":"Cap binding and immune evasion revealed by Lassa nucleoprotein structure","volume":"468","author":"Qi","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.tips.2013.11.006_bib0470","doi-asserted-by":"crossref","first-page":"19208","DOI":"10.1073\/pnas.1213553109","article-title":"Phleboviruses encapsidate their genomes by sequestering RNA bases","volume":"109","author":"Raymond","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tips.2013.11.006_bib0475","doi-asserted-by":"crossref","first-page":"11769","DOI":"10.1073\/pnas.1001760107","article-title":"Structure of the Rift Valley fever virus nucleocapsid protein reveals another architecture for RNA encapsidation","volume":"107","author":"Raymond","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tips.2013.11.006_bib0480","doi-asserted-by":"crossref","first-page":"7246","DOI":"10.1073\/pnas.1302298110","article-title":"Structural basis for encapsidation of genomic RNA by La Crosse Orthobunyavirus nucleoprotein","volume":"110","author":"Reguera","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tips.2013.11.006_bib0485","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/nbt.1638","article-title":"Identification of influenza A nucleoprotein as an antiviral target","volume":"28","author":"Kao","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.tips.2013.11.006_bib0490","doi-asserted-by":"crossref","first-page":"15366","DOI":"10.1073\/pnas.1107906108","article-title":"Inhibition of influenza virus replication via small molecules that induce the formation of higher-order nucleoprotein oligomers","volume":"108","author":"Gerritz","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tips.2013.11.006_bib0495","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/nature07120","article-title":"Crystal structure of the polymerase PA(C)\u2013PB1(N) complex from an avian influenza H5N1 virus","volume":"454","author":"He","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.tips.2013.11.006_bib0500","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1128\/AAC.01419-10","article-title":"Identification of high-affinity PB1-derived peptides with enhanced affinity to the PA protein of influenza A virus polymerase","volume":"55","author":"Wunderlich","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tips.2013.11.006_bib0505","doi-asserted-by":"crossref","first-page":"e7517","DOI":"10.1371\/journal.pone.0007517","article-title":"Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication","volume":"4","author":"Wunderlich","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.tips.2013.11.006_bib0510","doi-asserted-by":"crossref","first-page":"8414","DOI":"10.1074\/jbc.M110.205534","article-title":"Disruption of the viral polymerase complex assembly as a novel approach to attenuate influenza A virus","volume":"286","author":"Manz","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2013.11.006_bib0515","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s13238-013-3901-4","article-title":"The nucleoprotein of severe fever with thrombocytopenia syndrome virus processes a stable hexameric ring to facilitate RNA encapsidation","volume":"4","author":"Zhou","year":"2013","journal-title":"Protein Cell"},{"key":"10.1016\/j.tips.2013.11.006_bib0520","doi-asserted-by":"crossref","first-page":"12294","DOI":"10.1128\/JVI.01627-12","article-title":"Structure of Crimean-Congo haemorraghic fever virus nucleoprotein: superhelical homo-oligomers and the role of caspase-3 cleavage","volume":"86","author":"Wang","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2013.11.006_bib0525","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1016\/j.bmc.2007.01.036","article-title":"Optimization and determination of the absolute configuration of a series of potent inhibitors of human papillomavirus type-11 E1-E2 protein\u2013protein interaction: a combined medicinal chemistry, NMR and computational chemistry approach","volume":"15","author":"Goudreau","year":"2007","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.tips.2013.11.006_bib0530","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cell.2011.06.048","article-title":"Structural linkage between ligand discrimination and receptor activation by type I interferons","volume":"146","author":"Thomas","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.tips.2013.11.006_bib0535","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/ni.2229","article-title":"Intrinsic antiviral immunity","volume":"13","author":"Yan","year":"2012","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.tips.2013.11.006_bib0540","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.antiviral.2012.12.025","article-title":"Natural killer cell activity and function in chronic HCV-infected patients during peg interferon and ribavirin: early effects of active substance use","volume":"97","author":"Hotho","year":"2013","journal-title":"Antiviral Res."},{"key":"10.1016\/j.tips.2013.11.006_bib0545","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2165\/00003495-200262030-00009","article-title":"Interferon-\u03b1-2b plus ribavirin: a review of its use in the management of chronic hepatitis C","volume":"62","author":"Scott","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.tips.2013.11.006_bib0550","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1089\/107999002753675820","article-title":"Dynamics of hepatitis C virus monitored by real-time quantitative polymerase chain reaction during first 2 weeks of IFN-\u03b2 treatment are predictive of long-term therapeutic response","volume":"22","author":"Enomoto","year":"2002","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.tips.2013.11.006_bib0555","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S1386-6346(01)00113-9","article-title":"Interferon-\u03b3 brings additive anti-viral environment when combined with interferon-\u03b1 in patients with chronic hepatitis C","volume":"22","author":"Kumashiro","year":"2002","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.tips.2013.11.006_bib0560","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0168-8278(98)80053-6","article-title":"Treatment of chronic hepatitis C with \u03b1-interferon plus ofloxacin in patients not responding to \u03b1-interferon alone","volume":"29","author":"Negro","year":"1998","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tips.2013.11.006_bib0565","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/j.1440-1746.1996.tb00022.x","article-title":"Effects of combination therapy with interferon and ofloxacin on chronic type C hepatitis: a pilot study","volume":"11","author":"Tsutsumi","year":"1996","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tips.2013.11.006_bib0570","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1600-0676.1998.tb00819.x","article-title":"Interferon and thymosin combination therapy in naive patients with chronic hepatitis C: preliminary results","volume":"18","author":"Moscarella","year":"1998","journal-title":"Liver"},{"key":"10.1016\/j.tips.2013.11.006_bib0575","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00063030-200115070-00001","article-title":"Development of pegylated interferons for the treatment of chronic hepatitis C","volume":"15","author":"Kozlowski","year":"2001","journal-title":"BioDrugs"},{"key":"10.1016\/j.tips.2013.11.006_bib0580","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1126\/science.6238408","article-title":"Cyclophilin: a specific cytosolic binding protein for cyclosporin A","volume":"226","author":"Handschumacher","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.tips.2013.11.006_bib0585","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3390\/v5010182","article-title":"Insights into the roles of cyclophilin A during influenza virus infection","volume":"5","author":"Liu","year":"2013","journal-title":"Viruses"},{"key":"10.1016\/j.tips.2013.11.006_bib0590","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/0092-8674(91)90124-H","article-title":"Calcineurin is a common target of cyclophilin\u2013cyclosporin A and FKBP\u2013FK506 complexes","volume":"66","author":"Liu","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.tips.2013.11.006_bib0595","doi-asserted-by":"crossref","first-page":"e1000524","DOI":"10.1371\/journal.ppat.1000524","article-title":"Target cell cyclophilins facilitate human papillomavirus type 16 infection","volume":"5","author":"Bienkowska-Haba","year":"2009","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.tips.2013.11.006_bib0600","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1128\/JVI.02555-09","article-title":"Hepatitis B virus (HBV) surface antigen interacts with and promotes cyclophilin A secretion: possible link to pathogenesis of HBV infection","volume":"84","author":"Tian","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2013.11.006_bib0605","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1099\/vir.0.19074-0","article-title":"Requirement for cyclophilin A for the replication of vesicular stomatitis virus New Jersey serotype","volume":"84","author":"Bose","year":"2003","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.tips.2013.11.006_bib0610","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.bbrc.2004.07.003","article-title":"Nucleocapsid protein of SARS coronavirus tightly binds to human cyclophilin A","volume":"321","author":"Luo","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.tips.2013.11.006_bib0615","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.bbrc.2012.05.050","article-title":"Cyclophilin A inhibits rotavirus replication by facilitating host IFN-I production","volume":"422","author":"He","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.tips.2013.11.006_bib0620","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1128\/JVI.70.7.4299-4310.1996","article-title":"Binding of the human immunodeficiency virus type 1 Gag polyprotein to cyclophilin A is mediated by the central region of capsid and requires Gag dimerization","volume":"70","author":"Colgan","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2013.11.006_bib0625","doi-asserted-by":"crossref","first-page":"43202","DOI":"10.1074\/jbc.M305414200","article-title":"Cyclophilin A interacts with HIV-1 Vpr and is required for its functional expression","volume":"278","author":"Zander","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2013.11.006_bib0630","doi-asserted-by":"crossref","first-page":"43188","DOI":"10.1074\/jbc.M305413200","article-title":"Structural characterization of the HIV-1 Vpr N terminus: evidence of cis\/trans-proline isomerism","volume":"278","author":"Bruns","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2013.11.006_bib0635","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.bbapap.2012.02.002","article-title":"HIV-1 p6-Another viral interaction partner to the host cellular protein cyclophilin A","volume":"1824","author":"Solbak","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.tips.2013.11.006_bib0640","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1472-6807-11-49","article-title":"The host\u2013pathogen interaction of human cyclophilin A and HIV-1 Vpr requires specific N-terminal and novel C-terminal domains","volume":"11","author":"Solbak","year":"2011","journal-title":"BMC Struct. Biol."},{"key":"10.1016\/j.tips.2013.11.006_bib0645","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1053\/jhep.2003.50449","article-title":"Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes","volume":"38","author":"Watashi","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.tips.2013.11.006_bib0650","doi-asserted-by":"crossref","first-page":"6554","DOI":"10.1128\/JVI.02550-08","article-title":"Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex","volume":"83","author":"Liu","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2013.11.006_bib0655","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1128\/JVI.00328-07","article-title":"Identification of residues required for RNA replication in domains II and III of the hepatitis C virus NS5A protein","volume":"82","author":"Tellinghuisen","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2013.11.006_bib0660","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1182\/blood.V72.6.1904.1904","article-title":"The effect of cyclosporine A on infection of susceptible cells by human immunodeficiency virus type 1","volume":"72","author":"Wainberg","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.tips.2013.11.006_bib0665","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1128\/AAC.00939-08","article-title":"Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitor","volume":"53","author":"Coelmont","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tips.2013.11.006_bib0670","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1128\/AAC.00660-09","article-title":"SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro","volume":"54","author":"Hopkins","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tips.2013.11.006_bib0675","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1128\/AAC.01324-07","article-title":"Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent","volume":"52","author":"Ptak","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tips.2013.11.006_bib0680","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/01.aids.0000183633.06580.8a","article-title":"Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults","volume":"19","author":"Lalezari","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.tips.2013.11.006_bib0685","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1086\/650697","article-title":"Maraviroc versus efavirenz, both in combination with zidovudine\u2013lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection","volume":"201","author":"Cooper","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.tips.2013.11.006_bib0690","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jinf.2012.05.008","article-title":"Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: final results of two randomized phase III trials","volume":"65","author":"Caseiro","year":"2012","journal-title":"J. Infect."},{"key":"10.1016\/j.tips.2013.11.006_bib0695","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1128\/AAC.00713-10","article-title":"Pharmacokinetics and pharmacodynamics of TBR-652, a novel CCR5 antagonist, in HIV-1-infected, antiretroviral treatment-experienced, CCR5 antagonist-naive patients","volume":"55","author":"Marier","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tips.2013.11.006_bib0700","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/QAI.0b013e318213c2c0","article-title":"Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5\/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjects","volume":"57","author":"Lalezari","year":"2011","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.tips.2013.11.006_bib0705","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1126\/science.1241475","article-title":"Structure of the CCR5 chemokine receptor\u2013HIV entry inhibitor maraviroc complex","volume":"341","author":"Tan","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.tips.2013.11.006_bib0710","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1126\/science.1194396","article-title":"Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists","volume":"330","author":"Wu","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.tips.2013.11.006_bib0715","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nrmicro1389","article-title":"Parallels among positive-strand RNA viruses, reverse-transcribing viruses and double-stranded RNA viruses","volume":"4","author":"Ahlquist","year":"2006","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.tips.2013.11.006_bib0720","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1126\/science.1118398","article-title":"Structure of a V3-containing HIV-1 gp120 core","volume":"310","author":"Huang","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.tips.2013.11.006_bib0725","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nsmb.2255","article-title":"A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71","volume":"19","author":"Wang","year":"2011","journal-title":"Nat. Struct. Mol. Biol."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614713002265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614713002265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T09:23:25Z","timestamp":1648027405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614713002265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":145,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0165614713002265"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2013.11.006","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current progress in antiviral strategies","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2013.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}